Bayer halts vilaprisan drug trials due to toxicology data
Bayer said it halted trials testing its experimental uterine fibroids treatment vilaprisan, which it previously expected to generate peak annual sales of more than 1 billion euros ($1.1 billion), citing the risk of side effects. [Source]
Publication Date:Origin: reuters.com
Category: healthNews
Topics: bayer, trials, vilaprisan, experimental, uterine